Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | LIPE | Q05469 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CD4 | P01730 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382729 | 0.99 | EPHX2 (0.50) | EPHX2MEN1KMT2ALIPEEPHX1 | |
| SCHEMBL4380733 | 0.95 | EPHX2 (0.47) | EPHX2MEN1KMT2ALIPEEPHX1 | |
| SCHEMBL13589003 | 0.91 | HTR2A (0.49) | EPHX2MEN1KMT2ALIPEEPHX1 | |
| SCHEMBL4388306 | 0.90 | EPHX2 (0.43) | EPHX2MEN1KMT2ALIPEEPHX1 | |
| SCHEMBL4383533 | 0.90 | EPHX2 (0.43) | EPHX2MEN1KMT2ALIPEEPHX1 | |
| SCHEMBL4378966 | 0.89 | MEN1 (0.48) | EPHX2MEN1KMT2ALIPEEPHX1 | |
| SCHEMBL4386064 | 0.88 | EPHX2 (0.43) | EPHX2MEN1KMT2ALIPEEPHX1 | |
| SCHEMBL4384890 | 0.87 | EPHX2 (0.46) | EPHX2MEN1KMT2ALIPEEPHX1 | |
| SCHEMBL4385519 | 0.85 | EPHX2 (0.44) | EPHX2MEN1KMT2ALIPEEPHX1 | |
| SCHEMBL4388873 | 0.85 | EPHX2 (0.46) | EPHX2MEN1KMT2ALIPEEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | EPHX2 925/4885MEN1 3694/4885KMT2A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.